1
|
Di Ieva A. Computational Fractal-Based Analysis of MR Susceptibility-Weighted Imaging (SWI) in Neuro-Oncology and Neurotraumatology. ADVANCES IN NEUROBIOLOGY 2024; 36:445-468. [PMID: 38468047 DOI: 10.1007/978-3-031-47606-8_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/13/2024]
Abstract
Susceptibility-weighted imaging (SWI) is a magnetic resonance imaging (MRI) technique able to depict the magnetic susceptibility produced by different substances, such as deoxyhemoglobin, calcium, and iron. The main application of SWI in clinical neuroimaging is detecting microbleedings and venous vasculature. Quantitative analyses of SWI have been developed over the last few years, aimed to offer new parameters, which could be used as neuroimaging biomarkers. Each technique has shown pros and cons, but no gold standard exists yet. The fractal dimension (FD) has been investigated as a novel potential objective parameter for monitoring intratumoral space-filling properties of SWI patterns. We showed that SWI patterns found in different tumors or different glioma grades can be represented by a gradient in the fractal dimension, thereby enabling each tumor to be assigned a specific SWI fingerprint. Such results were especially relevant in the differentiation of low-grade versus high-grade gliomas, as well as from high-grade gliomas versus lymphomas.Therefore, FD has been suggested as a potential image biomarker to analyze intrinsic neoplastic architecture in order to improve the differential diagnosis within clinical neuroimaging, determine appropriate therapy, and improve outcome in patients.These promising preliminary findings could be extended into the field of neurotraumatology, by means of the application of computational fractal-based analysis for the qualitative and quantitative imaging of microbleedings in traumatic brain injury patients. In consideration of some evidences showing that SWI signals are correlated with trauma clinical severity, FD might offer some objective prognostic biomarkers.In conclusion, fractal-based morphometrics of SWI could be further investigated to be used in a complementary way with other techniques, in order to form a holistic understanding of the temporal evolution of brain tumors and follow-up response to treatment, with several further applications in other fields, such as neurotraumatology and cerebrovascular neurosurgery as well.
Collapse
Affiliation(s)
- Antonio Di Ieva
- Computational NeuroSurgery (CNS) Lab & Macquarie Neurosurgery, Macquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW, Australia.
| |
Collapse
|
2
|
Perez WD, Perez-Torres CJ. Neurocognitive and radiological changes after cranial radiation therapy in humans and rodents: a systematic review. Int J Radiat Biol 2023; 99:119-137. [PMID: 35511499 DOI: 10.1080/09553002.2022.2074167] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Radiation-induced brain injury is a common long-term side effect for brain cancer survivors, leading to a reduced quality of life. Although there is growing research pertaining to this topic, the relationship between cognitive and radiologically detected lesions of radiation-induced brain injury in humans remains unclear. Furthermore, clinically translatable similarities between rodent models and human findings are also undefined. The objective of this review is to then identify the current evidence of radiation-induced brain injury in humans and to compare these findings to current rodent models of radiation-induced brain injury. METHODS This review includes an examination of the current literature on cognitive and radiological characteristics of radiation-induced brain injury in humans and rodents. A thorough search was conducted on PubMed, Web of Science, and Scopus to identify studies that performed cognitive assessments and magnetic resonance imaging techniques on either humans or rodents after cranial radiation therapy. A qualitative synthesis of the data is herein reported. RESULTS A total of 153 studies pertaining to cognitively or radiologically detected radiation injury of the brain are included in this systematic review; 106 studies provided data on humans while 47 studies provided data on rodents. Cognitive deficits in humans manifest across multiple domains after brain irradiation. Radiological evidence in humans highlight various neuroimaging-detectable changes post-irradiation. It is unclear, however, whether these findings reflect ground truth or research interests. Additionally, rodent models do not comprehensively reproduce characteristics of cognitive and radiological injury currently identified in humans. CONCLUSION This systematic review demonstrates that associations between and within cognitive and radiological radiation-induced brain injuries often rely on the type of assessment. Well-designed studies that evaluate the spectrum of potential injury are required for a precise understanding of not only the clinical significance of radiation-induced brain injury in humans, but also how to replicate injury development in pre-clinical models.
Collapse
Affiliation(s)
- Whitney D Perez
- School of Health Sciences, Purdue University, West Lafayette, IN, USA
| | - Carlos J Perez-Torres
- School of Health Sciences, Purdue University, West Lafayette, IN, USA.,Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, USA.,Academy of Integrated Science, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.,School of Neuroscience, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA
| |
Collapse
|
3
|
Qin J, Yu Z, Yao Y, Liang Y, Tang Y, Wang B. Susceptibility-weighted imaging cannot distinguish radionecrosis from recurrence in brain metastases after radiotherapy: a comparison with high-grade gliomas. Clin Radiol 2022; 77:e585-e591. [PMID: 35676103 DOI: 10.1016/j.crad.2022.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 05/06/2022] [Indexed: 11/16/2022]
Abstract
AIM To explore the efficiency of susceptibility-weighted imaging (SWI) in the differential diagnosis of recurrence from radionecrosis in brain metastases (BM) and in high-grade gliomas (HGG). MATERIALS AND METHODS From September 2016 to November 2018, 56 patients with BM and 42 patients with HGG were included in this retrospective study. BM and HGG were assigned to the recurrence and radionecrosis groups according to their histopathology or follow-up results. The proportion of dark signal intensity (proDSI), which was defined as the area of dark signal on SWI or the enhancing area on contrast-enhanced T1-weighted imaging (T1WI), was calculated for each patient. Analysis of variance (ANOVA) with Tukey's honestly significant difference test was used for the repeat multiple comparisons. Receiver operating characteristic curve analysis was performed to validate the diagnostic performance. RESULTS For HGG, the proDSI in the recurrence group was significantly lower than that in the radionecrosis group (0.13 ± 0.05 versus 0.43 ± 0.11, p<0.001); however, for BM, no statistical difference was found between groups (0.49 ± 0.09 versus 0.46 ± 0.08, p=0.26). proDSI had the best diagnostic performance (AUC = 0.87, 95% CI: 0.76-0.98; sensitivity = 0.87; specificity = 0.88) for HGG, when a cut-off value of 0.21 was selected. CONCLUSIONS Semi-quantitative analysis using SWI is feasible for the differential diagnosis between recurrence and radionecrosis in HGG, but is not feasible in BM. Semi-quantitative assessment based on SWI should interpreted with caution in BM after radiotherapy in clinical practice.
Collapse
Affiliation(s)
- J Qin
- School of Medicine, Qingdao University, Qingdao, 266021, PR China; Department of Radiology, Rizhao Central Hospital, Rizhao, 276800, PR China
| | - Z Yu
- Department of Health Management Center, Qilu Hospital of Shandong University, Jinan, 250012, PR China; Nursing Theory & Practice Innovation Research Center of Shandong University, Jinan, 250012, PR China
| | - Y Yao
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, 250012, PR China
| | - Y Liang
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, 250012, PR China
| | - Y Tang
- Department of Radiology, Rizhao Central Hospital, Rizhao, 276800, PR China
| | - B Wang
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, 250012, PR China.
| |
Collapse
|
4
|
Haller OC, Aleksonis HA, Krishnamurthy LC, King TZ. White matter hyperintensities relate to executive dysfunction, apathy, but not disinhibition in long-term adult survivors of pediatric cerebellar tumor. Neuroimage Clin 2022; 33:102891. [PMID: 34922123 PMCID: PMC8686062 DOI: 10.1016/j.nicl.2021.102891] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2021] [Revised: 10/20/2021] [Accepted: 11/19/2021] [Indexed: 11/04/2022]
Abstract
Pediatric brain tumor survivors have more executive dysfunction than controls. White matter hyperintensities are positively associated with executive dysfunction. White matter hyperintensities are positively associated with apathy. Multivariate regression supports white matter hyperintensity associations. Survivors appear to drive white matter hyperintensities associations.
White matter hyperintensities (WMHs) have been related to executive dysfunction, apathy and disinhibition in a wide range of neurological populations. However, this relationship has not been examined in survivors of pediatric brain tumor. The goal of this study was to investigate how executive dysfunction, apathy, and disinhibition relate to WMHs in 31 long-term survivors of pediatric cerebellar brain tumor and 58 controls, using informant-report data from the Frontal Systems Behavior Scale. Total WMH volume was quantified using the Lesion Growth Algorithm. Further, periventricular, and subcortical volumes were identified based on proximity to custom ventricle masks generated in FSL. A ratio of WMH volume to whole brain volume was used to obtain normalized WMH volumes. Additionally, a multivariate regression analysis was performed. On average, informant-report scores were within normal limits and only executive dysfunction was significantly higher in survivors compared to controls (t(47.9) = -2.4, p=.023). Informants reported clinically significant levels of apathy in 32.3% of survivors. Informants also reported clinically significant executive dysfunction in 19.4 % of survivors and clinically significant disinhibition in, again, 19.4 % of survivors. Increased volume of WMHs was positively correlated with executive dysfunction (r = 0.33, p = 0.02) and apathy (r = 0.23, p = .04). Similarly, multivariate regression demonstrated correlations with executive dysfunction (p=.05, FDR corrected) and apathy (p=.05, FDR corrected). Exploratory analysis demonstrated an interaction wherein the relationship between total WMHs and executive dysfunction and apathy depends on whether the participant was a survivor. The current findings indicate that increased WMH volumes are associated with higher ratings of apathy and executive dysfunction, and that these results are likely unique to cerebellar brain tumor survivors. WMH burden may serve as a useful marker to identify survivors at risk of executive dysfunction or increased apathy.
Collapse
Affiliation(s)
- Olivia C Haller
- Department of Psychology, Georgia State University, Atlanta, GA, USA
| | - Holly A Aleksonis
- Department of Psychology, Georgia State University, Atlanta, GA, USA
| | - Lisa C Krishnamurthy
- Center for Visual and Neurocognitive Rehabilitation, Atlanta VA, Decatur, GA, USA; Department of Physics and Astronomy, Georgia State University, Atlanta, GA, USA
| | - Tricia Z King
- Department of Psychology, Georgia State University, Atlanta, GA, USA; Neuroscience Institute, Georgia State University, Atlanta, GA, USA.
| |
Collapse
|
5
|
Campbell BA, Lasocki A, Oon SF, Bressel M, Goroncy N, Dwyer M, Wiltshire K, Seymour JF, Mason K, Tange D, Xu M, Wheeler G. Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy. Clin Oncol (R Coll Radiol) 2021; 33:e425-e432. [PMID: 34024699 DOI: 10.1016/j.clon.2021.04.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 03/25/2021] [Accepted: 04/21/2021] [Indexed: 11/26/2022]
Abstract
AIMS Radiation-induced cavernomas (RIC) are common late toxicities in long-term survivors of malignancy following cerebral irradiation. However, the natural history of RIC is poorly described. We report the first series of long-term surveillance of RIC using modern magnetic resonance imaging (MRI) including highly sensitive susceptibility-weighted imaging (SWI). The aims of this research were to better characterise the natural history of RIC and investigate the utility of MRI-SWI for screening and surveillance. MATERIALS AND METHODS Eligibility required long-term survivors of malignancy with previous exposure to cerebral irradiation and RIC identified on MRI-SWI surveillance. The number and size of RIC were reported on Baseline MRI-SWI and last Follow-up MRI-SWI. RESULTS In total, 113 long-term survivors with RIC underwent MRI-SWI surveillance; 109 (96%) were asymptomatic at the time of RIC diagnosis. The median age at cerebral irradiation was 9.3 years; the median radiotherapy dose was 50.4 Gy. The median time from cerebral irradiation to Baseline MRI-SWI was 17.9 years. On Baseline MRI-SWI, RIC multiplicity was present in 89% of patients; 34% had >10 RIC; 65% had RIC ≥4 mm. The median follow-up from Baseline MRI-SWI was 7.3 years. On Follow-up MRI-SWI, 96% of patients had multiple RIC; 62% had >10 RIC; 72% had RIC ≥4 mm. Of the 109 asymptomatic patients at RIC diagnosis, 96% remained free from RIC-related symptoms at 10 years. Only two required neurosurgical intervention for RIC; there was no RIC-related mortality. CONCLUSIONS RIC are commonly multiple, asymptomatic and typically increase in size and number over time. Our findings suggest that MRI-SWI for screening of RIC is unlikely to influence longer term intervention in asymptomatic cancer survivors. In the absence of neurological symptoms, assessment or monitoring of RIC are insufficient indications for MRI-SWI surveillance for long-term survivors of malignancy with past exposure to cerebral irradiation.
Collapse
Affiliation(s)
- B A Campbell
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
| | - A Lasocki
- Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
| | - S F Oon
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
| | - M Bressel
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - N Goroncy
- Department of Cancer Nursing, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - M Dwyer
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - K Wiltshire
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - J F Seymour
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - K Mason
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - D Tange
- Department of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - M Xu
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - G Wheeler
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| |
Collapse
|
6
|
Witzmann K, Raschke F, Troost EGC. MR Image Changes of Normal-Appearing Brain Tissue after Radiotherapy. Cancers (Basel) 2021; 13:cancers13071573. [PMID: 33805542 PMCID: PMC8037886 DOI: 10.3390/cancers13071573] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 03/13/2021] [Accepted: 03/23/2021] [Indexed: 12/24/2022] Open
Abstract
Simple Summary Radiotherapy is one of the most important treatment options against cancer. Irradiation of cancerous tissue either directly destroys the cancer cells or damages them such that they cannot reproduce. One side-effect of radiotherapy is that tumor-surrounding normal tissue is inevitably also irradiated, albeit at a lower dose. The resulting long-term damage can significantly affect cognitive performance and quality of life. Many studies investigated the effect of irradiation on normal-appearing brain tissues and some of these correlated imaging findings with functional outcome. This article provides an overview of the examination of radiation-induced injuries using conventional and enhanced MRI methods and summarizes conclusions about the underlying tissue changes. Radiation-induced morphologic, microstructural, vascular, and metabolic tissue changes have been observed, in which the effect of irradiation was evident in terms of decreased perfusion and neuronal health as well as increased diffusion and atrophy. Abstract Radiotherapy is part of the standard treatment of most primary brain tumors. Large clinical target volumes and physical characteristics of photon beams inevitably lead to irradiation of surrounding normal brain tissue. This can cause radiation-induced brain injury. In particular, late brain injury, such as cognitive dysfunction, is often irreversible and progressive over time, resulting in a significant reduction in quality of life. Since 50% of patients have survival times greater than six months, radiation-induced side effects become more relevant and need to be balanced against radiation treatment given with curative intent. To develop adequate treatment and prevention strategies, the underlying cause of radiation-induced side-effects needs to be understood. This paper provides an overview of radiation-induced changes observed in normal-appearing brains measured with conventional and advanced MRI techniques and summarizes the current findings and conclusions. Brain atrophy was observed with anatomical MRI. Changes in tissue microstructure were seen on diffusion imaging. Vascular changes were examined with perfusion-weighted imaging and susceptibility-weighted imaging. MR spectroscopy revealed decreasing N-acetyl aspartate, indicating decreased neuronal health or neuronal loss. Based on these findings, multicenter prospective studies incorporating advanced MR techniques as well as neurocognitive function tests should be designed in order to gain more evidence on radiation-induced sequelae.
Collapse
Affiliation(s)
- Katharina Witzmann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology—OncoRay, Dresden, Germany; (K.W.); (F.R.)
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Felix Raschke
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology—OncoRay, Dresden, Germany; (K.W.); (F.R.)
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Esther G. C. Troost
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology—OncoRay, Dresden, Germany; (K.W.); (F.R.)
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany
- National Center for Tumor Diseases (NCT), Partner Site Dresden of the German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- Correspondence:
| |
Collapse
|
7
|
Kluge S, Balermpas P, Lehrnbecher T, Porto L. Pediatric CNS imaging and long-term effects of irradiation in pediatric oncology patients. Pediatr Int 2021; 63:81-87. [PMID: 32799347 DOI: 10.1111/ped.14409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 07/01/2020] [Accepted: 07/22/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND The aim of this study was to evaluate post-irradiation changes in the central nervous system (CNS) detected using magnetic resonance (MR) imaging. METHODS Magnetic resonance images of 15 children with CNS tumors treated through whole-brain irradiation over 10 years were reviewed retrospectively. Variables such as age at the time of irradiation, total radiation dose, treatment length, and time interval between irradiation and MR changes, were evaluated. RESULTS All patients included in the study had imaging abnormalities of the CNS. Eight patients (53%) developed CNS abnormalities within a short period of time - only a few months after irradiation (mean 4.8 months). Seven patients (47%) developed CNS abnormalities within a long time interval after treatment (mean 4.6 years). In almost all patients, a T2 increase in supra- and infratentorial white matter was observed. Follow-up examinations showed nine patients (60%) with cerebellar atrophy. CONCLUSIONS In this sample of pediatric patients who underwent whole-brain irradiation, the time receiving irradiation was not related to the severity of the MR changes. A correlation between the age of the child or the length of the radiotherapy and the extent of the changes could not be confirmed. However, we observed a trend towards stronger brain parenchymal degeneration with cystic changes in the younger age group of children in our sample. Older children who received irradiation seem to be more susceptible to vascular dysplasia with cavernous hemangiomas and microbleeding.
Collapse
Affiliation(s)
- Sara Kluge
- Institute of Neuroradiology, Frankfurt, Germany
| | - Panagiotis Balermpas
- Department of Radiation Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.,Department of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland
| | - Thomas Lehrnbecher
- Division for Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany
| | | |
Collapse
|
8
|
Quantifying effects of radiotherapy-induced microvascular injury; review of established and emerging brain MRI techniques. Radiother Oncol 2019; 140:41-53. [PMID: 31176207 DOI: 10.1016/j.radonc.2019.05.020] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 05/16/2019] [Accepted: 05/17/2019] [Indexed: 12/17/2022]
Abstract
Microvascular changes are increasingly recognised not only as primary drivers of radiotherapy treatment response in brain tumours, but also as an important contributor to short- and long-term (cognitive) side effects arising from irradiation of otherwise healthy brain tissue. As overall survival of patients with brain tumours is increasing, monitoring long-term sequels of radiotherapy-induced microvascular changes in the context of their potential predictive power for outcome, such as cognitive disability, has become increasingly relevant. Ideally, radiotherapy-induced significant microvascular changes in otherwise healthy brain tissue should be identified as early as possible to facilitate adaptive radiotherapy and to proactively start treatment to minimise the influence on these side-effects on the final outcome. Although MRI is already known to be able to detect significant long-term radiotherapy induced microvascular effects, more recently advanced MR imaging biomarkers reflecting microvascular integrity and function have been reported and might provide a more accurate and earlier detection of microvascular changes. However, the use and validation of both established and new techniques in the context of monitoring early and late radiotherapy-induced microvascular changes in both target-tissue and healthy tissue currently are minimal at best. This review aims to summarise the performance and limitations of existing methods and future opportunities for detection and quantification of radiotherapy-induced microvascular changes, as well as the relation of these findings with key clinical parameters.
Collapse
|
9
|
Takada A, Ii N, Hirayama M, Toyoda H, Matsubara T, Toyomasu Y, Kawamura T, Daimon T, Sakuma H, Nomoto Y. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor. J Neurosurg Pediatr 2019; 23:317-324. [PMID: 30497152 DOI: 10.3171/2018.9.peds18181] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Accepted: 09/06/2018] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The authors analyzed the efficacy of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumors (GCTs) and evaluated the long-term late effects caused by chemoradiotherapy (CRT). METHODS The authors performed a retrospective study. The subjects were 24 patients who received CRT between April 1994 and April 2015. After surgery, intensive chemotherapy followed by reduced-dose and reduced-field irradiation was administered. For those with pure germinoma, who comprised the “good prognosis” group, five courses of conventional-dose chemotherapy (CDC) were administered, and radiotherapy (24 Gy) was applied to the whole ventricle. For all others, defined as the “intermediate and poor prognosis” group, two or three courses of CDC and high-dose chemotherapy were administered with peripheral blood stem cell transplantation and radiotherapy (24–30 Gy) applied to the whole ventricle or a larger field with or without local boost irradiation (20 Gy), which was applied as needed. RESULTS The median period of follow-up was 112.5 months (range 28–261 months), and the 5-/10-year overall and progression-free survival rates were 100%/83.5% and 91.3%/86.5%, respectively. The 5-/10-year overall survival rates determined based on the histological subtypes were 100%/100% for pure germinoma and 93.8%/78.7% for others, respectively. The late toxicities were as follows: endocrine disorder (33% in pure germinoma, 56% in others), involuntary movements (17% in pure germinoma, 39% in others), ear and labyrinth disorders (17% in pure germinoma, 33% in others), and psychiatric disorders (0% in pure germinoma, 33% in others). Nineteen of 24 patients underwent MRI (T2*- or susceptibility-weighted imaging) after radiotherapy, and 16 (84%) of those 19 patients had microbleeds detected, while 2 (10.5%) had radiation-induced cavernous vascular malformations detected. CONCLUSIONS Intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial GCTs had the same outcome as that reported in the literature, but late adverse effects after treatment were observed. Almost all of the complications were relatively mild but had the potential to lead to psychiatric disorders and intracranial hemorrhaging. ABBREVIATIONS AFP = alpha-fetoprotein; CDC = conventional-dose chemotherapy; CMB = cerebral microbleed; CRT = chemoradiotherapy; CSI = craniospinal irradiation; EP = etoposide and cisplatin; GCT = germ cell tumor; HCG = human chorionic gonadotropin; HDC = high-dose chemotherapy; ICE = ifosfamide, cisplatin, and etoposide; NGGCT = nongerminomatous GCT; OS = overall survival; PBSCT = peripheral blood stem cell transplantation; PFS = progression-free survival; RICM = radiation-induced cavernous malformation; STGC = syncytiotrophoblastic giant cell; SWI = susceptibility-weighted imaging.
Collapse
Affiliation(s)
| | - Noriko Ii
- Department of Radiation Oncology, Ise Red Cross Hospital, Ise City, Mie
| | | | | | | | | | | | - Takashi Daimon
- Department of Biostatistics, Hyogo College of Medicine, Nishinomiya City, Hyogo; and
| | | | - Yoshihito Nomoto
- Radiation Oncology, Mie University Graduate School of Medicine, Tsu City, Mie, Japan
| |
Collapse
|
10
|
Radiation-Induced Cerebral Microbleeds in Pediatric Patients With Brain Tumors Treated With Proton Radiation Therapy. Int J Radiat Oncol Biol Phys 2018; 102:1465-1471. [PMID: 30092336 DOI: 10.1016/j.ijrobp.2018.07.2016] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 05/11/2018] [Accepted: 07/25/2018] [Indexed: 11/24/2022]
Abstract
PURPOSE Proton beam radiation therapy (PBT) has been increasingly used to treat pediatric brain tumors; however, limited information exists regarding radiation-induced cerebral microbleeds (CMBs) among these patients. The purpose of this study was to evaluate the incidence, risk factors, and imaging appearance of CMBs in pediatric patients with brain tumors treated with PBT. MATERIALS AND METHODS A retrospective study was performed of 100 pediatric patients with primary brain tumors treated with PBT. CMBs were diagnosed by examination of serial magnetic resonance imaging scans, including susceptibility-weighted imaging. Radiation therapy plans were analyzed to determine doses to individual CMBs. Clinical records were used to determine risk factors associated with the development of CMBs in these patients. RESULTS The mean age at time of PBT was 8.1 years. The median follow-up duration was 57 months. The median time to development of CMBs was 8 months (mean, 11 months; range, 3-28 months). The percentage of patients with CMBs was 43%, 66%, 80%, 81%, 83%, and 81% at 1 year, 2 years, 3 years, 4 years, 5 years, and >5 years from completion of proton radiation therapy. Most of the CMBs (87%) were found in areas of brain exposed to ≥30 Gy. Risk factors included maximum radiation therapy dose (P = .001), percentage and volume of brain exposed to ≥30 Gy (P = .0004, P = .0005), and patient age at time of PBT (P = .0004). Chemotherapy was not a significant risk factor (P = .35). No CMBs required surgical intervention. CONCLUSIONS CMBs develop in a high percentage of pediatric patients with brain tumors treated with proton radiation therapy within the first few years after treatment. Significant risk factors for development of CMBs include younger age at time of PBT, higher maximum radiation therapy dose, and higher percentage and volume of brain exposed to ≥30 Gy. These findings demonstrate similarities with CMBs that develop in pediatric patients with brain tumor treated with photon radiation therapy.
Collapse
|
11
|
Detection of cavernous malformations after whole-brain radiotherapy in primitive neuroectodermal tumor patients—comparing susceptibility-weighted imaging and T2 gradient-echo sequences. Neuroradiology 2018; 60:913-919. [DOI: 10.1007/s00234-018-2055-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Accepted: 07/06/2018] [Indexed: 10/28/2022]
|
12
|
Lecler A, Charbonneau F, Psimaras D, Metten MA, Gueguen A, Hoang Xuan K, Feuvret L, Savatovsky J. Remote brain microhaemorrhages may predict haematoma in glioma patients treated with radiation therapy. Eur Radiol 2018; 28:4324-4333. [PMID: 29651771 DOI: 10.1007/s00330-018-5356-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Revised: 01/03/2018] [Accepted: 01/26/2018] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To evaluate the prevalence of cerebral remote microhaemorrhages (RMH) and remote haematomas (RH) using magnetic resonance susceptibility-weighted imaging (SWI) among patients treated for gliomas during follow-up. METHODS We conducted a retrospective single centre longitudinal study on 58 consecutive patients treated for gliomas from January 2009 through December 2010. Our institutional review board approved this study. We evaluated the presence and number of RMH and RH found outside the brain tumour on follow-up MR imaging. We performed univariate and bivariate analyses to identify predictors for RMH and RH and Kaplan-Meier survival analysis techniques. RESULTS Twenty-five (43%) and four patients (7%) developed at least one RMH or RH, respectively, during follow-up. The risk was significantly higher for patients who received radiation therapy (49% and 8% versus 0%) (p = 0.02). The risk of developing RH was significantly higher in patients with at least one RMH and a high burden of RMH. The mean age of those presenting with at least one RMH or RH was significantly lower. CONCLUSIONS RMH were common in adult survivors of gliomas who received radiation therapy and may predict the onset of RH during follow-up, mainly in younger patients. KEY POINTS • Brain RMH and RH are significantly more likely to occur after RT. • RMH occur in almost half of the patients treated with RT. • RMH and RH are significantly more frequent in younger patients. • RH occur only in patients with RMH.
Collapse
Affiliation(s)
- Augustin Lecler
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, 25 rue Manin, 75019, Paris, France.
| | - Frédérique Charbonneau
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, 25 rue Manin, 75019, Paris, France
| | - Dimitri Psimaras
- Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France
| | - Marie-Astrid Metten
- Clinical Research Unit, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Antoine Gueguen
- Department of Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Khe Hoang Xuan
- Department of Neurooncology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France
| | - Loic Feuvret
- Department of Radiotherapy, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France
| | - Julien Savatovsky
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, 25 rue Manin, 75019, Paris, France.,Imagerie Medicale Paris 13, Paris, France
| |
Collapse
|
13
|
Neu MA, Tanyildizi Y, Wingerter A, Henninger N, El Malki K, Alt F, Doerr B, Schmidberger H, Stockinger M, Wagner W, Keweloh S, Brockmann MA, Russo A, Faber J. Susceptibility-weighted magnetic resonance imaging of cerebrovascular sequelae after radiotherapy for pediatric brain tumors. Radiother Oncol 2018; 127:280-286. [PMID: 29605477 DOI: 10.1016/j.radonc.2018.03.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 03/01/2018] [Accepted: 03/13/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND AND PURPOSE Due to sensitive neuroimaging techniques, cerebrovascular complications such as cerebral microbleeds (CMB) and cerebral cavernous malformations (CCM) are increasingly recognized as considerable late effects after treatment for pediatric brain tumor. The aim of this study was to analyze CMB in a cohort of patients after cranial irradiation therapy for medulloblastoma or other pediatric brain tumors using susceptibility-weighted magnetic resonance imaging (SWI). MATERIALS AND METHODS Forty former pediatric brain tumor patients were enrolled in this prospective cross-sectional study and examined by cranial MRI including SWI sequences. Cerebral microbleeds, clinical symptoms and disability were evaluated. RESULTS Thirty-six (90%) of the examined individuals (mean follow-up age 22.2 y; mean follow-up time 13.5 y) were affected by CMB. Longer follow-up time and higher craniospinal irradiation doses correlated with higher total lesion count (p < 0.01). Thirteen patients (32.5%) presented with clinical symptoms. Individuals with CMB were more severely disabled than patients without CMB (p < 0.05). CONCLUSIONS Cerebrovascular sequelae occur frequently after treatment for pediatric brain tumor. In this study, a remarkable part of pediatric brain tumor patients presents with CMB. As a sign of vascular damage, they can cause clinical symptoms and may correspond to neurocognitive decline. Further studies are needed to standardize MRI protocols and to improve quality of long-term follow-up.
Collapse
Affiliation(s)
- Marie A Neu
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | | | - Arthur Wingerter
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | - Nicole Henninger
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | - Khalifa El Malki
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | - Francesca Alt
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | - Barbara Doerr
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | - Heinz Schmidberger
- Department of Radiation Oncology and Radiation Therapy, University Medical Center Mainz, Germany
| | - Marcus Stockinger
- Department of Radiation Oncology and Radiation Therapy, University Medical Center Mainz, Germany
| | - Wolfgang Wagner
- Division of Pediatric Neurosurgery, Department of Neurosurgery, University Medical Center Mainz, Germany
| | - Stefanie Keweloh
- Department of Neuroradiology, University Medical Center Mainz, Germany
| | - Marc A Brockmann
- Department of Neuroradiology, University Medical Center Mainz, Germany
| | - Alexandra Russo
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany
| | - Joerg Faber
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Germany.
| |
Collapse
|
14
|
Miura M, Nakajima M, Fujimoto A, Kaku Y, Kawano T, Watanabe M, Kuratsu JI, Ando Y. High prevalence of small vessel disease long after cranial irradiation. J Clin Neurosci 2017; 46:129-135. [DOI: 10.1016/j.jocn.2017.09.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Revised: 07/24/2017] [Accepted: 09/04/2017] [Indexed: 11/27/2022]
|
15
|
Morana G, Alves CA, Tortora D, Finlay JL, Severino M, Nozza P, Ravegnani M, Pavanello M, Milanaccio C, Maghnie M, Rossi A, Garrè ML. T2*-based MR imaging (gradient echo or susceptibility-weighted imaging) in midline and off-midline intracranial germ cell tumors: a pilot study. Neuroradiology 2017; 60:89-99. [PMID: 29128947 DOI: 10.1007/s00234-017-1947-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 11/06/2017] [Indexed: 12/18/2022]
Abstract
PURPOSE The role of T2*-based MR imaging in intracranial germ cell tumors (GCTs) has not been fully elucidated. The aim of this study was to evaluate the susceptibility-weighted imaging (SWI) or T2* gradient echo (GRE) features of germinomas and non-germinomatous germ cell tumors (NGGCTs) in midline and off-midline locations. METHODS We retrospectively evaluated all consecutive pediatric patients referred to our institution between 2005 and 2016, for newly diagnosed, treatment-naïve intracranial GCT, who underwent MRI, including T2*-based MR imaging (T2* GRE sequences or SWI). Standard pre- and post-contrast T1- and T2-weighted imaging characteristics along with T2*-based MR imaging features of all lesions were evaluated. Diagnosis was performed in accordance with the SIOP CNS GCT protocol criteria. RESULTS Twenty-four subjects met the inclusion criteria (17 males and 7 females). There were 17 patients with germinomas, including 5 basal ganglia primaries, and 7 patients with secreting NGGCT. All off-midline germinomas presented with SWI or GRE hypointensity; among midline GCT, all NGGCTs showed SWI or GRE hypointensity whereas all but one pure germinoma were isointense or hyperintense to normal parenchyma. A significant difference emerged on T2*-based MR imaging among midline germinomas, NGGCTs, and off-midline germinomas (p < 0.001). CONCLUSION Assessment of the SWI or GRE characteristics of intracranial GCT may potentially assist in differentiating pure germinomas from NGGCT and in the characterization of basal ganglia involvement. T2*-based MR imaging is recommended in case of suspected intracranial GCT.
Collapse
Affiliation(s)
- Giovanni Morana
- Neuroradiology Unit, Istituto Giannina Gaslini, Genoa, Italy.
| | | | | | - Jonathan L Finlay
- Division of Hematology, Oncology and BMT, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, USA
| | | | - Paolo Nozza
- Pathology Unit, Istituto Giannina Gaslini, Genoa, Italy
| | | | | | | | - Mohamad Maghnie
- Pediatric Endocrine Unit, Istituto Giannina Gaslini, University of Genova, Genoa, Italy
| | - Andrea Rossi
- Neuroradiology Unit, Istituto Giannina Gaslini, Genoa, Italy
| | | |
Collapse
|
16
|
Kim TH, Yun TJ, Park CK, Kim TM, Kim JH, Sohn CH, Won JK, Park SH, Kim IH, Choi SH. Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients. Oncotarget 2017; 8:20340-20353. [PMID: 27823971 PMCID: PMC5386766 DOI: 10.18632/oncotarget.13050] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 10/28/2016] [Indexed: 01/14/2023] Open
Abstract
Purpose was to assess predictive power for overall survival (OS) and diagnostic performance of combination of susceptibility-weighted MRI sequences (SWMRI) and dynamic susceptibility contrast (DSC) perfusion-weighted imaging (PWI) for differentiation of recurrence and radionecrosis in high-grade glioma (HGG). We enrolled 51 patients who underwent radiation therapy or gamma knife surgeryfollowed by resection for HGG and who developed new measurable enhancement more than six months after complete response. The lesions were confirmed as recurrence (n = 32) or radionecrosis (n = 19). The mean and each percentile value from cumulative histograms of normalized CBV (nCBV) and proportion of dark signal intensity on SWMRI (proSWMRI, %) within enhancement were compared. Multivariate regression was performed for the best differentiator. The cutoff value of best predictor from ROC analysis was evaluated. OS was determined with Kaplan-Meier method and log-rank test. Recurrence showed significantly lower proSWMRI and higher mean nCBV and 90th percentile nCBV (nCBV90) than radionecrosis. Regression analysis revealed both nCBV90 and proSWMRI were independent differentiators. Combination of nCBV90 and proSWMRI achieved 71.9% sensitivity (23/32), 100% specificity (19/19) and 82.3% accuracy (42/51) using best cut-off values (nCBV90 > 2.07 and proSWMRI≤15.76%) from ROC analysis. In subgroup analysis, radionecrosis with nCBV > 2.07 (n = 5) showed obvious hemorrhage (proSWMRI > 32.9%). Patients with nCBV90 > 2.07 and proSWMRI≤15.76% had significantly shorter OS. In conclusion, compared with DSC PWI alone, combination of SWMRI and DSC PWI have potential to be prognosticator for OS and lower false positive rate in differentiation of recurrence and radionecrosis in HGG who develop new measurable enhancement more than six months after complete response.
Collapse
Affiliation(s)
- Tae-Hyung Kim
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Tae Jin Yun
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.,Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea
| | - Chul-Kee Park
- Department of Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
| | - Tae Min Kim
- Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
| | - Ji-Hoon Kim
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.,Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea
| | - Chul-Ho Sohn
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.,Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea
| | - Jae Kyung Won
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Sung-Hye Park
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Il Han Kim
- Department of Radiation Oncology, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
| | - Seung Hong Choi
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.,Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.,Center for Nanoparticle Research, Institute for Basic Science, Seoul, Republic of Korea
| |
Collapse
|
17
|
Relationship between radiation dose and microbleed formation in patients with malignant glioma. Radiat Oncol 2017; 12:126. [PMID: 28797254 PMCID: PMC5553662 DOI: 10.1186/s13014-017-0861-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 08/01/2017] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Cranial irradiation is associated with long-term cognitive changes. Cerebral microbleeds (CMBs) have been identified on susceptibility-weighted MRI (SWI) in patients who have received prior cranial radiation, and serve as radiographic markers for microvascular injury thought to contribute to late cognitive decline. The relationship between CMB formation and radiation dose has not previously been quantified. METHODS SWI was performed on 13 patients with stable WHO grade III-IV gliomas between 2 and 4 years after chemoradiotherapy to 60 Gy. The median age at the time of treatment was 41 years (range 25 - 74 years). CMBs were identified as discrete foci of susceptibility on SWI that did not correspond to vessels. CMB density for low (<30 Gy), median (30-45 Gy), and high (>45 Gy) dose regions was computed. RESULTS Twelve of 13 patients exhibited CMBs. The number of CMBs was significantly higher for late (>3 years from treatment) compared to early (<3 years) timepoints (early median 6 CMBs; late median 27 CMBs; p = 0.001), and there were proportionally more CMBs at lower doses for late scans (p = 0.006). 88% of all CMBs were observed in regions receiving at least 30 Gy, but the CMB density within medium and high dose regions was not significantly different (p = 0.33 and p = 0.9, respectively, for early and late time points). CONCLUSIONS CMBs predominantly form in regions receiving at least 30 Gy, but form in lower dose regions with longer follow-up. We do not observe a clear dose-response relationship at doses above 30 Gy. These findings provide important information to assess the risk of late microvascular sequelae from cranial irradiation.
Collapse
|
18
|
Russo A, Neu MA, Theruvath J, Kron B, Wingerter A, Hey-Koch S, Tanyildizi Y, Faber J. Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor. Childs Nerv Syst 2017; 33:1275-1283. [PMID: 28488085 DOI: 10.1007/s00381-017-3434-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 04/26/2017] [Indexed: 01/28/2023]
Abstract
PURPOSE Cerebrospinal cavernous malformations (CCMs) are vascular lesions characterized by dilated and leaky capillary caverns. CCMs can cause seizures, focal neurological deficits or acute intracranial hemorrhage; however, most patients are asymptomatic. CCMs occur either sporadically or as a familial autosomal-dominant disorder. We present a clinical and molecular study of a patient with distinctive cerebral and spinal cavernous malformations following radiochemotherapy for a malignant brain tumor. METHODS The patient had multiple magnet resonance imaging (MRI) examinations of his brain and spine following radiochemotherapy for a primary intracranial germ cell tumor (GCT), as part of his oncologic follow-up. The MRI sequences included susceptibility-weighted imaging (SWI). The coding exons and their flanking intronic regions of KRIT1/CCM1 gene were analyzed for mutations by polymerase chain reaction (PCR) and direct sequencing. RESULTS MRI revealed numerous cerebral and spinal microhemorrhages and pronounced cavernous malformations that progressed with subsequent follow-up imaging. Genetic analysis demonstrated a novel heterozygous KRIT1/CCM1 two base pair deletion (c.1535_1536delTG) in exon 14. This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein. CONCLUSION We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
Collapse
Affiliation(s)
- Alexandra Russo
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - Marie Astrid Neu
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - Johanna Theruvath
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - Bettina Kron
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - Arthur Wingerter
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - Silla Hey-Koch
- Department of Radiation Oncology and Radiation Therapy, University Medical Center Mainz, Mainz, Germany
| | - Yasemin Tanyildizi
- Department of Neuroradiology, University Medical Center Mainz, Mainz, Germany
| | - Joerg Faber
- Department of Pediatric Hematology/Oncology/Hemostaseology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
| |
Collapse
|
19
|
MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. J Immunol Res 2017; 2017:5813951. [PMID: 28512646 PMCID: PMC5415864 DOI: 10.1155/2017/5813951] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 02/06/2017] [Accepted: 03/02/2017] [Indexed: 01/14/2023] Open
Abstract
Pseudophenomena, that is, imaging alterations due to therapy rather than tumor evolution, have an important impact on the management of glioma patients and the results of clinical trials. RANO (response assessment in neurooncology) criteria, including conventional MRI (cMRI), addressed the issues of pseudoprogression after radiotherapy and concomitant chemotherapy and pseudoresponse during antiangiogenic therapy of glioblastomas (GBM) and other gliomas. The development of cancer immunotherapy forced the identification of further relevant response criteria, summarized by the iRANO working group in 2015. In spite of this, the unequivocal definition of glioma progression by cMRI remains difficult particularly in the setting of immunotherapy approaches provided by checkpoint inhibitors and dendritic cells. Advanced MRI (aMRI) may in principle address this unmet clinical need. Here, we discuss the potential contribution of different aMRI techniques and their indications and pitfalls in relation to biological and imaging features of glioma and immune system interactions.
Collapse
|
20
|
Passos J, Nzwalo H, Marques J, Azevedo A, Nunes S, Salgado D. Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of pediatric brain tumors. Neuro Oncol 2017; 19:298-299. [DOI: 10.1093/neuonc/now246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Roddy E, Sear K, Felton E, Tamrazi B, Gauvain K, Torkildson J, Buono BD, Samuel D, Haas-Kogan DA, Chen J, Goldsby RE, Banerjee A, Lupo JM, Molinaro AM, Fullerton HJ, Mueller S. Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro Oncol 2016; 18:1548-1558. [PMID: 27540084 DOI: 10.1093/neuonc/now163] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 06/23/2016] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND A specific form of small-vessel vasculopathy-cerebral microbleeds (CMBs)-has been linked to various types of dementia in adults. We assessed the incidence of CMBs and their association with neurocognitive function in pediatric brain tumor survivors. METHODS In a multi-institutional cohort of 149 pediatric brain tumor patients who received cranial radiation therapy (CRT) between 1987 and 2014 at age <21 years and 16 patients who did not receive CRT, we determined the presence of CMBs on brain MRIs. Neurocognitive function was assessed using a computerized testing program (CogState). We used survival analysis to determine cumulative incidence of CMBs and Poisson regression to examine risk factors for CMBs. Linear regression models were used to assess effect of CMBs on neurocognitive function. RESULTS The cumulative incidence of CMBs was 48.8% (95% CI: 38.3-60.5) at 5 years. Children who had whole brain irradiation developed CMBs at a rate 4 times greater than those treated with focal irradiation (P < .001). In multivariable analysis, children with CMBs performed worse on the Groton Maze Learning test (GML) compared with those without CMBs (Z-score -1.9; 95% CI: -2.7, -1.1; P < .001), indicating worse executive function when CMBs are present. CMBs in the frontal lobe were associated with worse performance on the GML (Z-score -2.4; 95% CI: -2.9, -1.8; P < .001). Presence of CMBs in the temporal lobes affected verbal memory (Z-score -2.0; 95% CI: -3.3, -0.7; P = .005). CONCLUSION CMBs are common and associated with neurocognitive dysfunction in pediatric brain tumor survivors treated with radiation.
Collapse
Affiliation(s)
- Erika Roddy
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Katherine Sear
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Erin Felton
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Benita Tamrazi
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Karen Gauvain
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Joseph Torkildson
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Benedict Del Buono
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - David Samuel
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Daphne A Haas-Kogan
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Josephine Chen
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Robert E Goldsby
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Anuradha Banerjee
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Janine M Lupo
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Annette M Molinaro
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Heather J Fullerton
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| | - Sabine Mueller
- School of Medicine University of California San Francisco (UCSF), San Francisco, California (E.R.); Department of Neurology UCSF, San Francisco, California (K.S., E.F., B.D.B., H.J.F., S.M.); D epartment of Radiology Children's Hospital Los Angeles, Los Angeles, California (B.T.); Department of Pediatrics, Washington University, St Louis, Missouri (K.G.); Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, California (J.T.); Department of Pediatrics, Valley Children's Hospital, Madera, California (D.S.); Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology UCSF, San Francisco, California (J.C.); Department of Pediatrics UCSF, San Francisco, California (R.E.G., A.B., S.M.); Department of Neurological Surgery UCSF, San Francisco, California (A.B., A.M.M., S.M.); Department of Radiology and Biomedical Imaging UCSF, San Francisco, California (J.M.L.); Department of Biostatistics and Epidemiology UCSF, San Francisco, California (A.M.M.)
| |
Collapse
|
22
|
Di Ieva A, Lam T, Alcaide-Leon P, Bharatha A, Montanera W, Cusimano MD. Magnetic resonance susceptibility weighted imaging in neurosurgery: current applications and future perspectives. J Neurosurg 2015. [PMID: 26207600 DOI: 10.3171/2015.1.jns142349] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Susceptibility weighted imaging (SWI) is a relatively new imaging technique. Its high sensitivity to hemorrhagic components and ability to depict microvasculature by means of susceptibility effects within the veins allow for the accurate detection, grading, and monitoring of brain tumors. This imaging modality can also detect changes in blood flow to monitor stroke recovery and reveal specific subtypes of vascular malformations. In addition, small punctate lesions can be demonstrated with SWI, suggesting diffuse axonal injury, and the location of these lesions can help predict neurological outcome in patients. This imaging technique is also beneficial for applications in functional neurosurgery given its ability to clearly depict and differentiate deep midbrain nuclei and close submillimeter veins, both of which are necessary for presurgical planning of deep brain stimulation. By exploiting the magnetic susceptibilities of substances within the body, such as deoxyhemoglobin, calcium, and iron, SWI can clearly visualize the vasculature and hemorrhagic components even without the use of contrast agents. The high sensitivity of SWI relative to other imaging techniques in showing tumor vasculature and microhemorrhages suggests that it is an effective imaging modality that provides additional information not shown using conventional MRI. Despite SWI's clinical advantages, its implementation in MRI protocols is still far from consistent in clinical usage. To develop a deeper appreciation for SWI, the authors here review the clinical applications in 4 major fields of neurosurgery: neurooncology, vascular neurosurgery, neurotraumatology, and functional neurosurgery. Finally, they address the limitations of and future perspectives on SWI in neurosurgery.
Collapse
Affiliation(s)
| | - Timothy Lam
- Division of Neurosurgery, Department of Surgery; and
| | - Paula Alcaide-Leon
- Division of Neuroradiology, Department of Radiology, St. Michael's Hospital, University of Toronto, Ontario, Canada
| | - Aditya Bharatha
- Division of Neuroradiology, Department of Radiology, St. Michael's Hospital, University of Toronto, Ontario, Canada
| | - Walter Montanera
- Division of Neuroradiology, Department of Radiology, St. Michael's Hospital, University of Toronto, Ontario, Canada
| | | |
Collapse
|
23
|
Lupo JM, Molinaro AM, Essock-Burns E, Butowski N, Chang SM, Cha S, Nelson SJ. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro Oncol 2015. [PMID: 26206774 DOI: 10.1093/neuonc/nov128] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Radiotherapy (RT) is an integral component in managing patients with glioma, but the damage it may cause to healthy brain tissue and quality of life is of concern. Susceptibility-weighted imaging (SWI) is highly sensitive to the detection of microbleeds that occur years after RT. This study's goals were to characterize the evolution of radiation-induced microbleeds in normal-appearing brain and determine whether the administration of an anti-angiogenic agent altered this process. METHODS Serial high-resolution SWI was acquired on 17 patients with high-grade glioma between 8 months and 4.5 years posttreatment with RT and adjuvant chemotherapy. Nine of these patients were also treated with the anti-angiogenic agent enzastaurin. Microbleeds were identified as discrete foci of susceptibility not corresponding to vessels, tumor, or postoperative infarct, and counted in normal-appearing brain. Analysis of covariance was performed to compare slopes of regression of individual patients' microbleed counts over time, Wilcoxon rank-sum tests examined significant differences in rates of microbleed formation between groups, and linear and quadratic mixed-effects models were employed. RESULTS The number of microbleeds increased with time for all patients, with initial onset occurring at 8-22 months. No microbleeds disappeared once formed. The average rate of microbleed formation significantly increased after 2 years post-RT (P < .001). Patients receiving anti-angiogenic therapy exhibited fewer microbleeds overall (P < .05) and a significant reduction in initial rate of microbleed appearance (P = .01). CONCLUSIONS We have demonstrated a dramatic increase in microbleed formation after 2 years post-RT that was decelerated by the concomitant administration of anti-angiogenic therapy, which may aid in determining brain regions susceptible to RT.
Collapse
Affiliation(s)
- Janine M Lupo
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| | - Annette M Molinaro
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| | - Emma Essock-Burns
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| | - Nicholas Butowski
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| | - Susan M Chang
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| | - Soonmee Cha
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| | - Sarah J Nelson
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California (J.M.L., E.E.-B., S.C., S.J.N.); Department of Neurosurgery, University of California San Francisco, San Francisco, California (A.M.M., N.B., S.M.C., S.C.); Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California (A.M.M.); Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California (S.J.N.)
| |
Collapse
|
24
|
The postirradiation incidence of cavernous angioma is higher in patients with childhood pineoblastoma or primitive neuroectodermal tumors than medulloblastoma. Childs Nerv Syst 2015; 31:901-7. [PMID: 25690449 DOI: 10.1007/s00381-015-2626-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 02/02/2015] [Indexed: 10/24/2022]
Abstract
PURPOSE The purpose of this study is to investigate the incidence of cavernous angioma (CVA) in long-term survivors of childhood embryonal tumors treated by cranial irradiation. MATERIALS AND METHODS Between 1990 and 2012, we treated 25 patients (13 males, 12 females) with embryonal tumors (17 medulloblastomas, 5 primitive neuroectodermal tumors (PNET), 3 pineoblastomas) with craniospinal irradiation. Follow-up ranged from 15.5 to 289.9 months, the irradiation dose to the whole neural axis from 18 to 36 Gy, and the total local dose from 49.6 to 60 Gy. All patients underwent follow-up magnetic resonance imaging (MRI) studies at least once a year, and the diagnosis of posttreatment CVA was based solely on MRI findings. RESULTS At the time of this writing, 18 were alive and free of the recurrence of the original disease or the development of secondary neoplasms other than CVA; another 2 were alive with medulloblastoma or diffuse astrocytoma. Posttreatment, 14 patients developed CVAs in the course of a median of 56.7 months; 13 of these presented with multiple CVAs. Patients who underwent radiation therapy (RT) at an age younger than 6 years developed multiple CVAs significantly earlier than those treated at a later age (p = 0.0110). Patients with PNET or pineoblastoma developed Zabramski type 1 and 2 CVA significantly earlier than did medulloblastoma patients (p = 0.0042). CONCLUSION We attribute the high rate of post-RT CVA in our long-term follow-up study of pediatric patients to the delivery of cranial irradiation for embryonal tumors, especially PNET and pineoblastoma, and recommend the regular, long-term follow-up of patients whose embryonal tumors were treated by cranial irradiation.
Collapse
|
25
|
Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma. Semin Radiat Oncol 2014; 24:248-58. [PMID: 25219809 DOI: 10.1016/j.semradonc.2014.06.008] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
This review explores how the integration of advanced imaging methods with high-quality anatomical images significantly improves the characterization, target definition, assessment of response to therapy, and overall management of patients with high-grade glioma. Metrics derived from diffusion-, perfusion-, and susceptibility-weighted magnetic resonance imaging in conjunction with magnetic resonance spectroscopic imaging, allows us to characterize regions of edema, hypoxia, increased cellularity, and necrosis within heterogeneous tumor and surrounding brain tissue. Quantification of such measures may provide a more reliable initial representation of tumor delineation and response to therapy than changes in the contrast-enhancing or T2 lesion alone and have a significant effect on targeting resection, planning radiation, and assessing treatment effectiveness. In the long term, implementation of these imaging methodologies can also aid in the identification of recurrent tumor and its differentiation from treatment-related confounds and facilitate the detection of radiationinduced vascular injury in otherwise normal-appearing brain tissue.
Collapse
|